期刊
PHARMACOGENOMICS
卷 18, 期 17, 页码 1595-1609出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0117
关键词
chemotherapy; clinical trials; combinatorial treatments; mouse models; omics; targeted therapy; triple-negative breast cancer
资金
- NIH [R01CA160514]
Breast cancer is composed of several well-recognized subtypes including estrogen receptor, progesterone receptor and HER2 triple-negative breast cancer (TNBC). Without available targeted therapy options, standard of care for TNBC remains chemotherapy. It is of interest to note that TNBC tumors generally have better responses to chemotherapy compared with other subtypes. However, patients without complete response account for approximately 80% of TNBC. Mounting evidence suggests significant heterogeneity within the TNBC subtype, and studies have focused on genetic targets with high rates of altered expression. Recent studies suggest clear possibilities for benefits from targeted therapy in TNBC. In this review, we summarize studies of targeted therapy, including within mouse models, and discuss their applications in the development of combinatorial treatments to treat TNBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据